Tuesday, the FDA approved DexCom Inc’s (NASDAQ:DXCM) Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM). The Dexcom Stelo Glucose Biosensor System is ...

San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...

San Diego device maker Dexcom has received the first FDA clearance for a continuous glucose monitor that doesn’t require a doctor’s prescription. The U.S. Food and Drug Administration cleared Dexcom’s ...

Dexcom's Stelo uses a wearable sensor, paired with an application on the user's smartphone or other smart device to continuously measure blood glucose levels. The device, intended for use in ...

Credit: Dexcom. The Dexcom Stelo Glucose Biosensor System is an integral CGM intended for individuals 18 years of age and older with or without diabetes who are not on insulin. The Food and Drug ...

The Food and Drug Administration has approved the first over-the-counter continuous glucose monitor. The Dexcom Stelo Glucose Biosensor System is an integrated CGM intended for anyone 18 years and ...

Monitoring your health stats, from steps to heart rate, can help you get a handle on your fitness goals. But lately, we've seen technology that takes things a step further, enabling at-home tracking ...

Authorization of Stelo integrated CGM extends to children without diabetes as well ...